Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women

24. april 2018 oppdatert av: Margit I. Berman, Dartmouth-Hitchcock Medical Center

Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women: A Randomized Controlled Trial

The primary aim of this project is to conduct a randomized controlled pilot study evaluating the feasibility and potential effectiveness of a newly developed combined Health At Every Size and Acceptance and Commitment Therapy (HAES/ACT) treatment, known as Accept Yourself! compared to a commercial behavioral weight loss program, Weight Watchers (WW). Obese women (BMI ≥ 30) with Major Depressive Disorder will be randomly assigned to one of these two treatments. Depression, physical health, and other psychosocial outcomes will be assessed prior to treatment, at post-treatment, and at 3, 6, 9, and 12-month follow up assessments.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

19

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03766
        • Dartmouth-Hitchcock Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • English-speaking
  • Major Depressive Disorder (assessed using the Structured Clinical Interview for DSM-IV, SCID-IV)
  • Body Mass Index (BMI) greater than or equal to 30
  • Not taking medications or on stable medication regimens (i.e. no medication changes for six weeks prior to enrollment or during the study)

Exclusion Criteria:

  • current substance dependence
  • history of psychotic symptoms
  • high risk of suicide/self-harm
  • current enrollment in a weight-loss program
  • weight loss surgery in the past year
  • current psychotherapy
  • inability to postpone weight loss or depression treatment interventions for the duration of the study
  • taking antipsychotic, tricyclic, or oral corticosteroid medication
  • unwilling to be randomized to the study treatments

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Accept Yourself! Intervention
Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
Atferdsmessig: Accept Yourself!
Andre navn:
  • HAES/ACT
Aktiv komparator: Behavioral Weight Loss
Weight Watchers groups
Atferdsmessig: Vektpassere

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in clinician assessed depression symptoms
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
As assessed by clinician rated Hamilton Depression Rating Scale (HAM-D)
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
Change in self-reported depression symptoms
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.
As assessed by Patient Health Questionnaire-9 (PHQ-9)
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month follow-up assessments.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in fasting Lipids
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 12 month follow-up.
At post-treatment (immediately following the three-month intervention) and at 12 month follow-up.
Change in systolic and diastolic blood pressure
Tidsramme: At post-treatment (immediately following the three-month intervention) and 12 month follow up
At post-treatment (immediately following the three-month intervention) and 12 month follow up
Change in fasting blood glucose
Tidsramme: At post-treatment (immediately following the three-month intervention) and 12 month follow up
At post-treatment (immediately following the three-month intervention) and 12 month follow up
Change in eating disorder symptoms, measured by the Eating Disorders Diagnostic Scale (EDDS)
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
Change in obesity-related quality of life, measured by the Obesity-Related Well-Being Questionnaire (ORWELL97)
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
Change in obesity stigma, measured by the Weight Self-Stigma Questionnaire (WSSQ)
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
At post-treatment (immediately following the three-month intervention) and at 3, 6, 9, and 12-month assessments.
Number of participants who did not complete an adequate dose of the intervention (at least 7 group visits)
Tidsramme: At post-treatment (immediately following the three-month intervention)
At post-treatment (immediately following the three-month intervention)
Change in weight
Tidsramme: At post-treatment (immediately following the three-month intervention) and 12 month follow up
Note that we are assessing weight change primarily as a safety measure (i.e., to demonstrate no significant weight gain in intervention group).
At post-treatment (immediately following the three-month intervention) and 12 month follow up
Change in self-reported physical activity
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
Change in cardiovascular fitness as assessed by six-minute walk test
Tidsramme: At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.
At post-treatment (immediately following the three-month intervention) and at 12-month follow-up.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Dartmouth-Hitchcock Medical Center

Samarbeidspartnere

Hitchcock Foundation

Etterforskere

  • Hovedetterforsker: Margit I Berman, Ph.D, Dartmouth College

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. august 2015

Primær fullføring (Faktiske)

7. mai 2017

Studiet fullført (Faktiske)

7. mai 2017

Datoer for studieregistrering

Først innsendt

14. juli 2015

Først innsendt som oppfylte QC-kriteriene

15. juli 2015

Først lagt ut (Anslag)

17. juli 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. april 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. april 2018

Sist bekreftet

1. april 2018

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • D15151

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Accept Yourself!

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Qatar

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere